Spatially fractionated radiation therapy (SFRT) delivers deliberate, heterogeneous dose distributions consisting of alternating high-dose peaks and low-dose valleys to manage bulky, locally advanced, or radioresistant malignancies. Implementing a physical brass GRID collimator offers a standardized, reproducible alternative to complex multileaf collimator (MLC) segments or lattice planning. While modern radiotherapy frequently explores virtual leaf sequencing, physical block collimation provides remarkable mechanical stability and minimizes planning optimization overhead. Clinical medical physicists and radiation oncologists must rigorously characterize the physical transmission, output factors, and beam profiles of these specialized devices before deploying them in clinical workflows. This article reviews the dosimetric commissioning, validation benchmarks, and practical therapeutic implications associated with adopting a commercial brass GRID collimator across multiple megavoltage beam energies.

Physical Principles and Setup of the Brass GRID Collimator

Physical GRID collimation relies on a dense, machined block—typically manufactured from machinable brass—fitted into the accessory tray of a medical linear accelerator. This specialized device incorporates a matrix of divergent, conical holes configured in hexagonal or rectilinear arrays. Consequently, radiation incident upon the collimator passes unimpeded through the circular apertures while experiencing significant attenuation beneath the inter-hole septum. This geometry produces steep lateral dose gradients throughout the irradiated volume. In standard clinical practice, treating physicians leverage these alternating peaks and valleys to deliver single ablative fractions ranging from 10 Gy to 20 Gy to massive lesions without inducing catastrophic normal tissue necrosis. Furthermore, modern linear accelerators can operate these collimators using both flattening filter (FF) and flattening filter-free (FFF) modes. Flattening filter-free beams deliver markedly higher dose rates, which shortens total delivery time and mitigates intrafraction patient motion during massive single-fraction treatments.

Dosimetric Measurements and Valley-to-Peak Ratios

Accurate commissioning requires rigorous dosimetric data acquisition in a full-scatter water phantom using high-resolution detectors, such as micro-ionization chambers, edge diodes, and calibrated radiochromic films. Because the beamlets represent small-field geometries, detector volume averaging presents a significant risk during peak and valley characterization. Dosimetric assessments demonstrate that percentage depth dose (PDD) curves for brass GRID fields shift toward shallower depths compared to conventional open fields. This altered profile occurs due to beam hardening through the brass, electron disequilibrium, and scatter deficits within individual sub-centimeter apertures. Furthermore, the valley-to-peak dose ratio (VPDR) represents the primary metric governing normal tissue sparing and biological response. Experimental trials evaluate VPDR values across various energies, recording ratios between 0.20 and 0.30 for 6 MV beams and 0.30 to 0.37 for 10 MV beams. Higher photon energies exhibit greater Compton scatter and secondary electron transport, which inherently elevates the valley dose relative to low-energy photons.

Treatment Planning System Modeling and Profile Validation

Accurate commissioning of a brass GRID collimator depends on reproducing steep penumbral regions within the commercial treatment planning system (TPS). To achieve this, physicists introduce the physical aperture into the planning software either as a dedicated external accessory, an explicit base-plate block, or a dense transmission structure. Dose calculation algorithms—specifically advanced collapsed cone convolution superposition or grid-based Boltzmann solvers—must calculate profiles using a fine calculation grid resolution, ideally 1 mm. Measured versus calculated lateral profiles consistently show remarkable agreement, adhering to tight tolerances within ±5% in dose and 1 mm in distance-to-agreement across both 6 MV and 10 MV configurations. Additionally, pre-treatment quality assurance plans verified on two-dimensional high-resolution detector arrays achieve high clinical fidelity. Evaluations demonstrate average gamma passing rates of 96.5% under stringent 3%/3 mm criteria, proving that modern planning algorithms accurately model the intense physical modulation created by dense brass apertures.

Biological Rationale and Clinical Advantages

Beyond technical dosimetry, the biological rationale for GRID-based therapy extends far beyond standard linear-quadratic cell survival models. When clinicians treat massive, poorly vascularized tumors, the high-dose peaks trigger extensive microvascular damage, endothelial cell apoptosis, and tumor debulking. Concurrently, the lower-dose valley regions preserve surviving capillary networks and viable circulating lymphocytes, preventing central ischemic necrosis while promoting an influx of immune mediators. Additionally, this non-uniform irradiation prompts rapid cytokine cascades—such as elevated levels of tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β)—that stimulate bystander effects in adjacent, un-irradiated malignant cells. By deploying a prefabricated brass collimator, oncology teams bypass the labor-intensive forward planning and high monitor unit (MU) delivery associated with MLC-based step-and-shoot delivery. Consequently, clinics can initiate urgent palliative treatments for symptomatic masses promptly, avoiding prolonged optimization delays or mechanical leaf-travel constraints.

Operational Considerations and Practical Implementation

Although physical brass collimation presents distinct planning and delivery benefits, medical physicists must navigate notable physical constraints during routine clinical integration. First, a solid brass block represents a substantial physical weight, demanding careful ergonomic handling, dedicated storage carts, and strict safety interlocks to prevent mechanical drop hazards. Second, commercial collimator frames generally restrict the maximum field size to 25 × 25 cm² at isocenter, requiring composite dual-field alignment or complementary electron shields when treating exceptionally extensive pelvic or retroperitoneal masses. Third, radiation oncology teams must establish robust daily quality assurance protocols, verifying mechanical alignment, tray indexing, and optical accessory verification switches before beam ignition. Despite these practical handling demands, the platform remains an accessible, cost-effective, and highly robust mechanism for centers lacking dedicated stereotactic planning licenses, providing an efficient route to deliver safe, ablative spatial fractionation.

Frequently Asked Questions (FAQs)

What is the primary clinical advantage of a brass GRID collimator over multileaf collimators?

A brass GRID collimator delivers highly reproducible, physical spatial fractionation without requiring intricate multileaf collimator optimization or high monitor unit segment sequences. This mechanical approach streamlines treatment planning, drastically reduces beam delivery times, and provides exceptional mechanical durability. Furthermore, it completely eliminates machine wear and potential delivery discrepancies that can arise from complex, dynamic leaf trajectories during massive ablative single-fraction treatments.

Why does the valley-to-peak dose ratio increase with higher photon energies like 10 MV?

The valley-to-peak dose ratio increases at higher beam energies primarily because energetic photons produce longer-range secondary electrons and increased lateral Compton scattering. Consequently, more scattered radiation penetrates sideways into the shielded valley regions beneath the solid brass partitions. This lateral electron migration raises the baseline valley dose, moderately reducing the relative depth of modulation compared to lower-energy 6 MV photon fields.

Can clinicians safely combine GRID therapy with subsequent conventional fractionation?

Clinicians frequently and safely administer GRID therapy as an initial cytoreductive boost, typically delivering 10 to 20 Gy in a single fraction, followed by definitive or palliative conventional fractionated radiotherapy. Because the valley regions sustain sublethal exposure, healthy adjacent stroma and microvasculature recover rapidly, allowing patients to undergo subsequent standard chemoradiation schedules with minimal excess normal tissue toxicity.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals must exercise independent clinical judgment, evaluate specific clinical presentations, and verify manufacturer technical manuals, institutional policies, and commissioning data. Refer to the latest local and national guidelines for clinical practice.

References

1. Yaparpalvi R et al. Clinical commissioning of a commercial brass GRID collimator for spatially fractionated radiotherapy. Med Dosim. 2026 Sep 26. doi: undefined. PMID: 42800748.


2. Billi F, et al. Dosimetric characterization for GRID collimator-based spatially fractionated radiation therapy: Dosimetric parameter acquisition and machine interchangeability investigation. J Appl Clin Med Phys. 2024;25(7):e14389.


3. Zhang H, et al. An International Consensus on the Design of Prospective Clinical-Translational Trials in Spatially Fractionated Radiation Therapy. Adv Radiat Oncol. 2022;7(2):100866.


4. Alfonso R, et al. A new formalism for reference dosimetry of small and nonstandard fields. Med Phys. 2008;35(11):5179-5186.